141 related articles for article (PubMed ID: 4086243)
1. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
Dodion P; Davis TA; Rozencweig M; Crespeigne N; Kenis Y; Bachur NR
Invest New Drugs; 1985; 3(4):361-8. PubMed ID: 4086243
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
Kreis W; Rottach C; Budman DR; Chan K; Schulman P; Allen SL; Weiselberg L; Vinciguerra V
Cancer Res; 1988 Oct; 48(19):5580-4. PubMed ID: 3166400
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
[TBL] [Abstract][Full Text] [Related]
4. Human pharmacokinetics of marcellomycin.
Dodion P; Rozencweig M; Nicaise C; Watthieu M; Tamburini JM; Riggs CE; Bachur NR
Cancer Chemother Pharmacol; 1985; 14(1):42-8. PubMed ID: 3965159
[TBL] [Abstract][Full Text] [Related]
5. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia.
Dutcher JP; Riggs CE; Strauman JJ; Link B; Wiernik PH
Clin Pharmacol Ther; 1989 Apr; 45(4):424-8. PubMed ID: 2702800
[TBL] [Abstract][Full Text] [Related]
7. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography.
Peng YM; Alberts DS; Salmon SE; Davis TP
Invest New Drugs; 1984; 2(3):277-80. PubMed ID: 6511234
[TBL] [Abstract][Full Text] [Related]
8. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats.
Lee SD; Lee WI; Shim HJ; Lee ED; Kim WB; Yang J; Kim CK; Lee MG
J Clin Pharm Ther; 1996 Aug; 21(4):201-13. PubMed ID: 8933293
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
Vaughn CB; Salmon SE; Fleming TR
Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
14. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of 4'-deoxydoxorubicin given weekly.
Sessa C; Bosia L; Kaplan S; Pusterla C; Varini M; Cavalli F
Invest New Drugs; 1984; 2(4):369-73. PubMed ID: 6511241
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
Rozencweig M; Crespeigne N; Kenis Y
Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
Miller AA; Schmidt CG
Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.
Pratt CB; Douglass EC; Meyer WH; Hayes FA; Horowitz ME; Thompson EI; Avery L
Invest New Drugs; 1989 Jul; 7(2-3):209-11. PubMed ID: 2793374
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Bos AM; de Vries EG; Dombernovsky P; Aamdal S; Uges DR; Schrijvers D; Wanders J; Roelvink MW; Hanauske AR; Bortini S; Capriati A; Crea AE; Vermorken JB
Cancer Chemother Pharmacol; 2001 Nov; 48(5):361-9. PubMed ID: 11761453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
